Shire PLC’s (SHP) “Conviction-Buy” Rating Reaffirmed at Goldman Sachs Group Inc.
Goldman Sachs Group Inc. reaffirmed their conviction-buy rating on shares of Shire PLC (LON:SHP) in a research report sent to investors on Thursday. The brokerage currently has a GBX 6,300 ($82.23) price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. HSBC cut Shire PLC to a hold rating and dropped their price objective for the stock from GBX 5,400 ($70.49) to GBX 5,250 ($68.53) in a report on Monday. JPMorgan Chase & Co. reissued an overweight rating on shares of Shire PLC in a report on Friday, September 23rd. Shore Capital reissued a buy rating on shares of Shire PLC in a report on Wednesday. Citigroup Inc. reissued a buy rating on shares of Shire PLC in a report on Tuesday. Finally, Berenberg Bank reissued a buy rating and set a GBX 5,800 ($75.71) price objective on shares of Shire PLC in a report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5002.00 on Thursday. The company’s market cap is GBX 34.15 billion. The stock has a 50 day moving average of GBX 4,985.30 and a 200 day moving average of GBX 4,508.27. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 8th will be paid a dividend of GBX 3.51 ($0.05) per share. This represents a yield of 0.07%. The ex-dividend date is Thursday, September 8th.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.